agilon health, inc. (AGL)
| Market Cap | 1.54B +37.7% |
| Revenue (ttm) | 5.82B -2.8% |
| Net Income | -354.54M |
| EPS | -21.38 |
| Shares Out | 16.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 240,450 |
| Open | 91.46 |
| Previous Close | 90.37 |
| Day's Range | 88.00 - 93.90 |
| 52-Week Range | 7.48 - 94.71 |
| Beta | 2.30 |
| Analysts | Hold |
| Price Target | 60.36 (-34.59%) |
| Earnings Date | May 6, 2026 |
About AGL
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Westerville, Ohio.
Financial Performance
In 2025, agilon health's revenue was $5.93 billion, a decrease of -2.11% compared to the previous year's $6.06 billion. Losses were -$391.35 million, 50.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for AGL stock is "Hold." The 12-month stock price target is $60.36, which is a decrease of -34.59% from the latest price.
News
Agilon Health upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Andrew Mok upgraded Agilon Health (AGL) to Equal Weight from Underweight with an $81 price target The firm says the outlook for value-based care has “materially improved in…
Agilon Health price target raised to $95 from $13 at Benchmark
Benchmark analyst Bill Sutherland raised the firm’s price target on Agilon Health (AGL) to $95 from $13 and keeps a Buy rating on the shares. Following “remarkable” year-to-date performance, the…
Agilon Health price target raised to $80 from $18.75 at Citi
Citi raised the firm’s price target on Agilon Health (AGL) to $80 from $18.75 and keeps a Neutral rating on the shares.
Agilon Health price target raised to $55 from $17 at TD Cowen
TD Cowen raised the firm’s price target on Agilon Health (AGL) to $55 from $17 and keeps a Hold rating on the shares.The firm updated its model following better than…
Agilon Health price target raised to $72 from $37.50 at Wells Fargo
Wells Fargo raised the firm’s price target on Agilon Health (AGL) to $72 from $37.50 and keeps an Overweight rating on the shares. The firm is encouraged by Q1 results…
Agilon Health price target raised to $22 from $6.25 at BofA
BofA analyst Craig Jones raised the firm’s price target on Agilon Health (AGL) to $22 from $6.25 and keeps an Underperform rating on the shares. The firm revised estimates to…
Agilon Health Is Up 115% After Earnings. Why the Stock Is Having Its Best Day Ever.
Shares of Agilon Health cratered in 2025, driven by financial underperformance and a guidance suspension.
Agilon Health price target raised to $35 from $20 at Baird
Baird raised the firm’s price target on Agilon Health (AGL) to $35 from $20 and keeps a Neutral rating on the shares. The firm updated its model following strong Q1…
Agilon Health price target raised to $32 from $16 at Evercore ISI
Evercore ISI raised the firm’s price target on Agilon Health (AGL) to $32 from $16 and keeps an In Line rating on the shares.
Agilon Health upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Agilon Health (AGL) to Buy from Hold with a price target of $49, up from $33. The firm cites the improving macro environment and “compelling” share valuation…
Agilon Health upgraded to Buy from Hold at Jefferies
Jefferies analyst Jack Slevin upgraded Agilon Health (AGL) to Buy from Hold with a price target of $48, up from $27.50. The company’s “strong” Q1 results and “clear signs” of…
Agilon Health reports Q1 EPS $1.80, consensus 93c
Reports Q1 revenue $1.42B, consensus $1.38B. “Our strong first-quarter performance and increase in full-year 2026 guidance reflects disciplined execution and progress against our strategic priorities....
Agilon Health sees FY26 revenue $5.68B-$5.81B, consensus $5.45B
Sees FY26 total members 525K-540K.
agilon health Earnings Call Transcript: Q1 2026
First quarter results exceeded expectations, driven by operational discipline, improved data, and AI integration. Full-year 2026 guidance was raised, with strong clinical program expansion and continued focus on cost management and payer contracting.
agilon health Earnings release: Q1 2026
agilon health released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
agilon health Quarterly report: Q1 2026
agilon health has published its Q1 2026 quarterly earnings report on May 6, 2026.
agilon health Reports First Quarter 2026 Results
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the first quarte...
Agilon Health downgraded to Underweight from Neutral at JPMorgan
JPMorgan downgraded Agilon Health (AGL) to Underweight from Neutral with an unchanged price target of $21. The firm believes it will take several quarters for investors to confidently underwrite a…
Agilon Health names Tim O’Rourke as new CEO
agilon health (AGL) “announced the appointment of Tim O’Rourke as Chief Executive Officer and a member of the Company’s Board of Directors, effective May 7. He succeeds Ronald A. Williams,…
agilon health Appoints Tim O'Rourke as Chief Executive Officer
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health (NYSE: AGL) (the “Company”), the trusted partner empowering physicians to transform health care in our communities, today announced the appointment of...
agilon health Proxy statement: Proxy filing
agilon health filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
agilon health Proxy statement: Proxy filing
agilon health filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
agilon health Proxy statement: Proxy filing
agilon health filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Agilon Health price target raised to $17 from 60c at TD Cowen
TD Cowen raised the firm’s price target on Agilon Health (AGL) to $17 from 60c and keeps a Hold rating on the shares. The firm updated its model to reflect…
Did agilon health, inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...